United Therapeutics Corporation to Present at the RBC Capital Markets Global Healthcare Conference

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) announced today that James Edgemond, Chief Financial Officer and Treasurer, will provide a company overview and update on Tuesday, May 19, 2026, from 9:30 to 9:55 a.m. EST, at the RBC Capital Markets Global Healthcare Conference in New York. The presentation can be accessed via a live webcast on the United Therapeutics website at https://ir.unither.com/events-and-presentations. An.

Business Wire • 13 hours ago

United Therapeutics Corporation Presents New Data from TETON-1, ADVANCE OUTCOMES, and Additional Research in Pulmonary Hypertension and Pulmonary Fibrosis at ATS 2026

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that 12 new data presentations across its commercial and development portfolio will be presented at the American Thoracic Society (ATS) International Conference, May 15-20, in Orlando. “We are thrilled to share additional positive data from the TETON-1 study in IPF and the ADVANCE OUTCOMES study in PAH, our pivotal studies that achieve.

Business Wire • May 11, 2026

UTHR Q1 Earnings Miss Estimates, Shares Jump on Strong Outlook

United Therapeutics shares rise after Q1 earnings miss estimates as investors focus on Tyvaso IPF data and ralinepag's blockbuster potential.

Zacks Investment Research • May 7, 2026

United Therapeutics Corporation (UTHR) Q1 2026 Earnings Call Transcript

United Therapeutics Corporation (UTHR) Q1 2026 Earnings Call Transcript

Seeking Alpha • May 6, 2026

United Therapeutics Corporation Reports First Quarter 2026 Financial Results

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended March 31, 2026. Total revenues in the first quarter of 2026 decreased by two percent year-over-year to $781.5 million, compared to $794.4 million in the first quarter of 2025. “In the first quarter of 2026, we extended our run of clinical success, with positive results from both our ADVANCE O.

Business Wire • May 6, 2026

United Therapeutics (UTHR) Misses Q1 Earnings and Revenue Estimates

United Therapeutics (UTHR) came out with quarterly earnings of $5.82 per share, missing the Zacks Consensus Estimate of $6.73 per share. This compares to earnings of $6.63 per share a year ago.

Zacks Investment Research • May 6, 2026

Ahead of United Therapeutics (UTHR) Q1 Earnings: Get Ready With Wall Street Estimates for Key Metrics

Evaluate the expected performance of United Therapeutics (UTHR) for the quarter ended March 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Zacks Investment Research • May 5, 2026

Will United Therapeutics (UTHR) Beat Estimates Again in Its Next Earnings Report?

United Therapeutics (UTHR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks Investment Research • May 4, 2026

Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?

Looking for broad exposure to the Healthcare - Biotech segment of the equity market? You should consider the First Trust NYSE Arca Biotechnology ETF (FBT), a passively managed exchange traded fund launched on June 19, 2006.

Zacks Investment Research • Apr 30, 2026

United Therapeutics Corporation Announces Retirement of Professor Raymond Dwek, C.B.E., F.R.S., From Its Board of Directors

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the term for Professor Raymond Dwek, C.B.E., F.R.S., as a member of the Board of Directors will expire at the 2026 Annual Meeting of Shareholders, scheduled for June 26, 2026. Prof. Dwek, who is widely recognized for his pioneering work at Oxford University in the field of glycobiology, joined the United Therapeutics Board in 2002.

Business Wire • Apr 29, 2026